

Dr Nat Lenzo



Dr Lenzo completed undergraduate Medical Science degree (BMedSci(Hons) - 1988) and then Medical degree (MBBS-1991) at the University of Western Australia (UWA). He also has a BSc (ECU-1994).

Dr Lenzo trained in General Medicine and Nuclear Medicine in Australia and admitted as a fellow of RACP (2000). He is a member of ANZSNM, AANMS and SNMMI. He is also a fellow of the AANMS.

He has completed a Fellowship in Nuclear Medicine at the University of Michigan (1999/2000) and has completed additional post-graduate Master's degrees in Medicine and Health Service Management (MMed, MHSMgt - ECU), Business Administration (EMBA - UWA) and Advanced Oncology (MSc- Ulm).

He is a Graduate of the Australian Institute of Company Directors (AICD).

He previously held positions of Head of Department of Nuclear Medicine at Royal Perth Hospital; Inaugural Head of WA PET-Cyclotron Service, Sir Charles Gairdner Hospital, Perth and Head of Acute and General Medicine at Fremantle Hospital in Western Australia.

He has over 50 publications in peer reviewed journals predominantly in the areas of molecular imaging and Theranostics. He has presented over 150 abstracts at national and international meetings.

He currently holds adjunct positions as Clinical Professor in Medicine at both Curtin University in Perth and Notre Dame University in Fremantle, Western Australia.

He helped set up specialist medical practices, PET and cyclotron centres in Australia and Indonesia.

He has supervised trainees in General Medicine, Nuclear medicine and supervised masters and PhD students over the last 20 years.

Dr Lenzo founded Theranostics Australia in 2015. This was acquired by GenesisCare in 2017/2018 to help start their Theranostics division. GenesisCare is the largest private oncology organisation worldwide with around 6000 employees across 3 continents. GenesisCare currently has 5 Theranostics centres in Australia, 3 in the UK and 11 in the USA. This will double in scale over the next 24 months. GenesisCare has access to over 30 PET cameras across its network and is now the largest provider of Theranostics globally.

In 2020 Dr Lenzo founded CycloWest – a private GMP PET and therapy radiopharmaceutical + cyclotron facility. Currently in process of expanding into other Australasian markets.

Dr Lenzo was the first medical specialist in Australia to treat patients with Lu177-PSMA, Ac225-PSMA & Ac225-DOTATATE in prostate and other cancers.

He is PI/Al on 6 current theranostic trials (phase I, II and III) in prostate cancer, bladder cancer and NETs.

He is currently involved in training North American and Indonesian physicians in PSMA PET reporting.

Dr Lenzo is on a number of advisory committees including industry representative on the National Imaging Facility advisory committee, the industry committee for the Centre of Innovation in Biomedical Imaging and Technology, the Policy and Advocacy committee for the RACP and the Theranostics Working Party for the RANZCR. He is on the GE Global Advisory Board in Theranostics.

